within Pharmacolibrary.Drugs.ATC.N;

model N06BX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06BX09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Linopirdine is a synthetic compound that acts as a potassium channel blocker, specifically inhibiting KCNQ (Kv7) channels. It was investigated as a potential treatment for Alzheimer's disease and other cognitive disorders due to its ability to increase acetylcholine release. However, it was never approved for clinical use and is not marketed for any medical indication.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data has been found for linopirdine in humans or animals. The following parameters are estimated based on available phase 1 trial details and typical properties of compounds with similar chemical structure and intended CNS exposure.</p><h4>References</h4><ol><li><p>Pieniaszek, HJ, et al., &amp; Martz, R (1995). Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers. <i>Journal of clinical pharmacology</i> 35(1) 22–30. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1995.tb04741.x&quot;>10.1002/j.1552-4604.1995.tb04741.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7751410/&quot;>https://pubmed.ncbi.nlm.nih.gov/7751410</a></p></li><li><p>Chorvat, RJ, et al., &amp; Brown, BS (1998). Ion channel modulators that enhance acetylcholine release: potential therapies for Alzheimer&#x27;s disease. <i>Expert opinion on investigational drugs</i> 7(4) 499–518. DOI:<a href=&quot;https://doi.org/10.1517/13543784.7.4.499&quot;>10.1517/13543784.7.4.499</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15991988/&quot;>https://pubmed.ncbi.nlm.nih.gov/15991988</a></p></li><li><p>Hussain, MA, et al., &amp; Aungst, BJ (1990). Nasal administration of a cognition enhancer provides improved bioavailability but not enhanced brain delivery. <i>Journal of pharmaceutical sciences</i> 79(9) 771–772. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600790904&quot;>10.1002/jps.2600790904</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2273456/&quot;>https://pubmed.ncbi.nlm.nih.gov/2273456</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06BX09;
